Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12977746 | 0.93 | LMNA (0.45) | CCR1KCNH2 | |
| SCHEMBL2776482 | 0.93 | CCR1 (0.46) | CCR1KCNH2 | |
| SCHEMBL12846872 | 0.92 | LMNA (0.44) | CCR1KCNH2 | |
| SCHEMBL2774870 | 0.91 | CCR1 (0.52) | CCR1KCNH2 | |
| SCHEMBL2774241 | 0.91 | CCR1 (0.52) | CCR1KCNH2 | |
| SCHEMBL2775515 | 0.91 | EPHX2 (0.44) | CCR1KCNH2 | |
| SCHEMBL2775953 | 0.90 | LMNA (0.44) | CCR1KCNH2 | |
| SCHEMBL2774618 | 0.90 | CCR1 (0.44) | CCR1KCNH2 | |
| SCHEMBL2775999 | 0.90 | CCR1 (0.46) | CCR1KCNH2 | |
| SCHEMBL2775023 | 0.90 | LIPE (0.46) | CCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | claimed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | claimed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258697-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009119537-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | 第一三共株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053933-A1 | HYDROXYQUINOXALINECARBOXAMIDE DERIVATIVE | F12, F2, C3AR1 | CCR1 1428/4885KCNH2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.